References

Real-world data: towards achieving the achievable in cancer care

10.1038/s41571-019-0167-7 · 2019 · External reference

Real-world evidence: better than nothing or the future? A perspective on clinical evidence generation in interventional oncology

10.1007/s00270-025-04179-4 · 2026 · External reference

Comparative effectiveness research using randomized trials and observational studies: validity and feasibility considerations

10.1055/a-2664-7887 · 2026 · External reference

Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE registry-2

10.1055/a-2316-5269 · 2024 · External reference

Risk of major bleeding with antiplatelet and/or anticoagulation therapy in inherited factor XI deficiency: insights from real-world observations

10.1055/a-2347-4338 · 2025 · External reference

Impact of atrial fibrillation on thrombotic complications in myeloproliferative neoplasms real-world analysis

2026 · External reference

Cardiovascular safety in oncology clinical trials: JACC: cardiooncology primer

10.1016/j.jaccao.2024.09.014 · 2025 · External reference

Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports

2022 · External reference

Oncologic benefits and cardiovascular risks of pembrolizumab: insights from a nationwide lung adenocarcinoma cohort

10.1016/j.jacasi.2026.07.019 · 2026 · External reference

Generalisability of common oncology clinical trial eligibility criteria in the real world

10.1016/j.clon.2019.05.003 · 2019 · External reference

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

10.1016/s1470-2045(18)30608-9 · 2018 · External reference

Differential cardiotoxicity of ibrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a population-based study

10.3390/jcm13237492 · 2024 · External reference

Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis

10.1080/10428194.2026.2653123 · 2026 · External reference

Immortal time bias in national cancer database studies

10.1016/j.ijrobp.2019.07.056 · 2020 · External reference

The timing, the treatment, the question: Comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example

10.1158/1055-9965.epi-22-0495 · 2022 · External reference

Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?

10.57264/cer-2025-0186 · 2026 · External reference

Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators

10.1002/pds.5407 · 2022 · External reference

Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants

10.2217/cer-2020-0013 · 2020 · External reference

Competing risks data in clinical oncology

2024 · External reference

Target trial emulation for regulatory and clinical decision making in cancer

10.1200/jco-25-01906 · 2026 · External reference